---
{"dg-publish":true,"permalink":"/Reference notes/Readwise/Tweets/Hypertrophic Cardiomyopa.../"}
---

# Hypertrophic Cardiomyopa...

![rw-book-cover](https://pbs.twimg.com/profile_images/1493350073706717185/w8pDrNmU.jpg)

## Metadata
- Author: [[@LeonardChiuMD on Twitter\|@LeonardChiuMD on Twitter]]
- Full Title: Hypertrophic Cardiomyopa...
- Category: #tweets
- URL: https://twitter.com/LeonardChiuMD/status/1685754161629982720

## Highlights
- Hypertrophic cardiomyopathy is one of the most common causes of Sudden Cardiac Arrest in young adults. What is #HCM exactly?
  A üßµ on Hypertrophic Cardiomyopathy...1/24
  We'll cover:
  1) Dx criteria
  2) Pathophys
  3) Prevalence
  4) Natural hx & Clinical clues
  5) Management & NEW Tx 
  ![](https://pbs.twimg.com/media/F2T7S8tWkAAo4b4.jpg) ([View Tweet](https://twitter.com/LeonardChiuMD/status/1685754161629982720))
- First, what is #HCM?
  Clinically diagnosed: unexplained LVH
  ‚û°Ô∏è Not accounted by pressure overload: HTN, aortic stenosis
  ‚û°Ô∏è Not accounted by infiltration: amyloid or Fabry‚Äôs
  By ECHO in adults:
  ‚û°Ô∏è Ventricular wall ‚â•15 mm in absence of other dx
  ‚û°Ô∏è Family hx of HCM: wall ‚â•13 mm
  /2 ([View Tweet](https://twitter.com/LeonardChiuMD/status/1685754164356247553))
- What is the pathophys of HCM?
  - Pathogenic variants in sarcomere gene
  - 75% of ‚Äú+ve genetic testing‚Äù have mutations:
  ‚û°Ô∏è Myosin binding protein C (MYBPC3)
  ‚û°Ô∏è Myosin binding heavy chain (MYH7)
  üìå Mutations ‚¨ÜÔ∏è force & ‚¨áÔ∏è sarcomere relaxation
  ‚ùì 50% no identified genetic cause
  /3 
  ![](https://pbs.twimg.com/media/F2T41Q1XUAAL7sl.jpg) ([View Tweet](https://twitter.com/LeonardChiuMD/status/1685754165492854784))
- Moving on to Prevalence.
  What is the population estimate of hypertrophic cardiomyopathy prevalence?
  /4 ([View Tweet](https://twitter.com/LeonardChiuMD/status/1685754168542208000))
- Answer: The estimate is 1:500. Around 600,000 cases in the US.
  üö® HCM is the most common monogenic heart disease
  How about symptoms to look out for?
  - Exertional dyspnea
  - Angina
  - Palpitations
  - Orthopnea/PND
  - Syncope or presyncope (esp in pts w/ LVOT obstruction)
  /5 ([View Tweet](https://twitter.com/LeonardChiuMD/status/1685754170140151808))
- How about physical exam findings?
  - Systolic murmur LSB
  - Radiates to RUSB & apex
  - Murmur intensify w/ ‚¨áÔ∏è preload (Valsalva, squat-to-stand; see @BradLander18 @mmartinezheart @ACCinTouch
  - Murmur soften w/ ‚¨ÜÔ∏è afterload (passive ‚¨ÜÔ∏è LE, clench fists)
  /6
  https://t.co/GoBU9PiEM8 ([View Tweet](https://twitter.com/LeonardChiuMD/status/1685754171331338240))
- What is the natural history of HCM?
  ‚û°Ô∏è Most are asymptomatic (~60%)
  ‚û°Ô∏è Cumulative burden: those dx earlier, ‚¨ÜÔ∏è events
  üö® Most common dx burden:ü´ÄFailure & Afib
  ‚û°Ô∏è LVOT: systolic anterior motion of MV & MR
  üîë Outcomes most prevalent after 50y
  /7 
  ![](https://pbs.twimg.com/media/F2T6JrFXkAAkuz_.jpg) ([View Tweet](https://twitter.com/LeonardChiuMD/status/1685754173332058112))
- What EF defines LV w/ systolic dysfunction or ‚Äúburned-out‚Äù phase in HCM?
  /8 ([View Tweet](https://twitter.com/LeonardChiuMD/status/1685754175659945984))
- Answer: <50%
  HCM is normally associated w/ a hyperdynamic LV...so when EF <50%, end-stage HCM has a poor prognosis. Prevalence ~8%.
  Natural history of "burned-out" HCM:
  üö® 75% experienced adverse event
  ‚ò†Ô∏è 35% death/transplant/LVAD
  ‚û°Ô∏è At median time 8.4 yrs from recognition
  /9 
  ![](https://pbs.twimg.com/media/F2T7C-XWcAAi9sd.jpg) ([View Tweet](https://twitter.com/LeonardChiuMD/status/1685754176846835712))
- Moving on to types of HCM:
  1) Non-obstructive HCM (nHCM) ~1/3 of pts
  2) Obstructive HCM (oHCM) ~2/3 of pts
  ‚û°Ô∏è gradients at rest or exercise >30 mmHg
  This is an important distinction as this will guide management discussed later.
  /10 ([View Tweet](https://twitter.com/LeonardChiuMD/status/1685754178948251648))
- What imaging/tests to order to distinguish nHCM & oHCM?
  ‚û°Ô∏è Exercise ECHO: provokable gradients
  ‚û°Ô∏è CMR: identify SAM, LVOT
  ‚û°Ô∏è LHC: +ve Brockenborough-Braunwald-Morrow sign (1961)
  +ve sign: s/p PVC induction‚ö°Ô∏è, LV SBP ‚¨ÜÔ∏è & aortic pulse pressure ‚¨áÔ∏è (see below Fig 2 vs in AS)
  /11 
  ![](https://pbs.twimg.com/media/F2T7zzgXMAA6xtF.jpg) ([View Tweet](https://twitter.com/LeonardChiuMD/status/1685754179975831552))
- Moving on to management.
  Symptoms drive management.
  No symptoms? No need for therapy.
  For patients with oHCM and symptoms, what is the first line treatment? 
  /12 ([View Tweet](https://twitter.com/LeonardChiuMD/status/1685754181552947200))
- A: Metoprolol
  2020 ACC/AHA Guidelines (oHCM + symp):
  ‚úÖ BB 1st-line
  ‚úÖ Non-dihydropyrid CCBs (if ineffective)
  ‚úÖ Disopyramide or SRT (symp persist)
  Optimize pre + after-load:
  ‚ö†Ô∏è Cautious w/ diuretics
  ‚õîÔ∏è Avoid vasodilators
  ‚ùóÔ∏è Treat tachycardia
  ‚úÖ IV phenylephrine for acute hypo 
  ![](https://pbs.twimg.com/media/F2T8ZnjXcAED9Mo.png) ([View Tweet](https://twitter.com/LeonardChiuMD/status/1685754182790217728))
- Moving on to invasive treatment of symptomatic patients w/ oHCM.
  What are the indications for septal reduction therapy? /14 ([View Tweet](https://twitter.com/LeonardChiuMD/status/1685754184652521472))
- A: Both.
  Symptoms impair QoL despite medical therapy.
  Usually NYHA functional class III or IV.
  2 options:
  1‚É£ Surgical Myectomy
  2‚É£ Septal Ablation
  Choice depends:
  ‚û°Ô∏è suitable coronary anatomy (septal perf. artery for ablation)
  ‚û°Ô∏è extensive LVH or MV dx (favors myectomy)
  /15 ([View Tweet](https://twitter.com/LeonardChiuMD/status/1685754185763954688))
- How about for patients with end-stage non-obstructive HCM (nHCM)?
  A pt w. nHCM + afib p/w volume overload. LVEF <50%.
  What changes in management are you considering? /16 ([View Tweet](https://twitter.com/LeonardChiuMD/status/1685754187064176642))
- A:
  ‚úÖ Anticoagulation for ALL HCM pts w/ afib
  ‚úÖ Consider GDMT (ARNi/ACEi/ARB, MRA)
  üö´ Stop -ve inotropic agents (verapamil, diltiazem, disopyramide) unless for rate-control AF
  ‚úÖ Consider ICD for primary prevention
  ‚ö†Ô∏è RCTs excluded HCM & HF pts; consider on a case-by-case /17 ([View Tweet](https://twitter.com/LeonardChiuMD/status/1685790191506657281))
- Moving on to risk stratification for sudden cardiac death.
  Which HCM patient below should be considered for an ICD? /18 ([View Tweet](https://twitter.com/LeonardChiuMD/status/1685790192735539200))
- Answer: All of the above.
  All are Class 2A recommendations ("ICD is reasonable") from the ACC/AHA 2020 HCM Guidelines.
  If patient has had a prior event (SCD, VF, Sustained VT)
  ‚úÖ Class 1: ICD recommended
  /19 
  ![](https://pbs.twimg.com/media/F2UgUQJXMAAGO79.jpg) ([View Tweet](https://twitter.com/LeonardChiuMD/status/1685790193779953665))
- How about family screening and genetic testing?
  A 35 yo man is diagnosed with genetic HCM. You recommend genetic testing and surveillance for his 12 yo son. How often should his son receive surveillance screening? /20 ([View Tweet](https://twitter.com/LeonardChiuMD/status/1685790195721846784))
- Answer: Every 1-2 yrs
  There is an age-dependent penetrance to HCM. Serial screening is required:
  ‚úÖ Physical exam
  ‚úÖ ECHO
  ‚úÖ ECG
  The younger the age of diagnosis, the more frequent the surveillance for 1st degree relatives.
  For pt's 50 yo sister. Surveillance every 3-5 yrs 
  ![](https://pbs.twimg.com/media/F2UhlEzX0AA2yh-.jpg) ([View Tweet](https://twitter.com/LeonardChiuMD/status/1685793448450768896))
- How about sports & exercising with HCM?
  ‚úÖ Mild-mod intensity recreational exercise is recommended
  Recently (May 2023), LIVE-HCM Study @JAMACardio showed vigorous exercise in pts w/ HCM did not ‚¨ÜÔ∏è mortality or ‚¨ÜÔ∏è incidence of ventric. arrhythmias
  Shared decision w/ pts üîë
  /22 
  ![](https://pbs.twimg.com/media/F2UhzeYW0AIBEiY.jpg) 
  ![](https://pbs.twimg.com/media/F2Uh0VBXIAAya5b.jpg) ([View Tweet](https://twitter.com/LeonardChiuMD/status/1685793449784573952))
- Finally, how about disease-modifying therapy?
  In April 2022, @US_FDA approved the only current therapy for symptomatic oHCM:
  ‚úÖ Mavacamtem: cardiac myosin inhibitor
  Dr. Braunwald 1st described "hypertrophic subaortic stenosis‚Äù in 1964, elaborates here: https://t.co/AD7aP6L93j ([View Tweet](https://twitter.com/LeonardChiuMD/status/1685793452028514304))
- The approval was based on:
  EXPLORER-HCM:
  ‚û°Ô∏è Mavacamten vs placebo ‚¨ÜÔ∏è exercise capacity & health status in oHCM (LVOT>50 mmHg)
  VALOR-HCM:
  ‚û°Ô∏è Mavacamten ‚¨áÔ∏è eligibity for needing SRT vs placebo among oHCM (considering SRT + on max tx)
  Aficamten (another CMI) is promising...
  /24 
  ![](https://pbs.twimg.com/media/F2UituCXsAAngU8.jpg) 
  ![](https://pbs.twimg.com/media/F2UiuuFXAAE2Ufz.jpg) ([View Tweet](https://twitter.com/LeonardChiuMD/status/1685793453706227712))
- üö® Takeaways üö®
  üìå Key diagnostic feature: unexplained LVH
  üìå Mgmt for symptoms depends on pathophys (oHCM, nHCM, restrictive, LVSD)
  üìå Importance of family surveillance + genetic testing
  üìåNEW + other exciting disease-modifying txs to come...
  /Fin ([View Tweet](https://twitter.com/LeonardChiuMD/status/1685793455836917770))
- That was a lot. Thanks for following along!
  And thank you to everyone who has played a part in revolutionizing/raising awareness on #HCM 
  @MasriAhmad @MKIttlesonMD @srihariNaiduMD @ReshadGaranMD @UTahirMD @MJAckermanMDPhD @MartinMaronMD @LindenfeldJoann ([View Tweet](https://twitter.com/LeonardChiuMD/status/1685793457103687680))
- My main source in addition to links in thread:
  https://t.co/wW4VjNSyJ4
  @YevgeniyBr @HanCardiomd @AHajduczok @akhadilkarMD @DrJohnMcP @VUMCMedicineRes @vumccardsfit @HollyGHeartMed ([View Tweet](https://twitter.com/LeonardChiuMD/status/1685793458282225665))
